352 related articles for article (PubMed ID: 15121040)
1. An economic approach to health care.
Homik JE; Suarez-Almazor M
Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):203-18. PubMed ID: 15121040
[TBL] [Abstract][Full Text] [Related]
2. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis.
Choi HK; Seeger JD; Kuntz KM
J Rheumatol; 2002 Jun; 29(6):1156-65. PubMed ID: 12064828
[TBL] [Abstract][Full Text] [Related]
3. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
Kobelt G; Lindgren P; Singh A; Klareskog L
Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
[TBL] [Abstract][Full Text] [Related]
6. [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].
Merkesdal S; Ruof J
Z Rheumatol; 2002; 61 Suppl 2():II/29-32. PubMed ID: 12491120
[TBL] [Abstract][Full Text] [Related]
7. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Maetzel A; Strand V; Tugwell P; Wells G; Bombardier C
Arthritis Rheum; 2002 Dec; 47(6):655-61. PubMed ID: 12522841
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment.
Kobelt G; Lekander I; Lang A; Raffeiner B; Botsios C; Geborek P
Int J Technol Assess Health Care; 2011 Jul; 27(3):193-200. PubMed ID: 21736857
[TBL] [Abstract][Full Text] [Related]
10. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
Ollendorf DA; Peterson AN; Doyle J; Huse DM
Am J Manag Care; 2002 May; 8(7 Suppl):S203-13. PubMed ID: 12022236
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis.
Inotai A; Mészáros A
Int J Technol Assess Health Care; 2009 Apr; 25(2):190-5. PubMed ID: 19366498
[TBL] [Abstract][Full Text] [Related]
12. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis.
Choi HK; Seeger JD; Kuntz KM
Arthritis Rheum; 2000 Oct; 43(10):2316-27. PubMed ID: 11037892
[TBL] [Abstract][Full Text] [Related]
13. A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics.
Farahani P; Levine M; Goeree R
J Eval Clin Pract; 2006 Aug; 12(4):463-70. PubMed ID: 16907691
[TBL] [Abstract][Full Text] [Related]
14. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
Doan QV; Chiou CF; Dubois RW
J Manag Care Pharm; 2006 Sep; 12(7):555-69. PubMed ID: 16981801
[TBL] [Abstract][Full Text] [Related]
15. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
[TBL] [Abstract][Full Text] [Related]
17. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Spiegel BM; Chiou CF; Ofman JJ
Arthritis Rheum; 2005 Apr; 53(2):185-97. PubMed ID: 15818647
[TBL] [Abstract][Full Text] [Related]
18. Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s).
Cox ER; Motheral B; Mager D
Am J Manag Care; 2003 Dec; 9(12):785-94. PubMed ID: 14712755
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of etanercept in the management of chronic plaque psoriasis.
Lloyd A; Reeves P; Conway P; Reynolds A; Baxter G
Br J Dermatol; 2009 Feb; 160(2):380-6. PubMed ID: 18808413
[TBL] [Abstract][Full Text] [Related]
20. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.
Tanno M; Nakamura I; Ito K; Tanaka H; Ohta H; Kobayashi M; Tachihara A; Nagashima M; Yoshino S; Nakajima A
Mod Rheumatol; 2006; 16(2):77-84. PubMed ID: 16633926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
